Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal groups A, C, Y, and W-135 polysaccharide vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal groups A, C, Y, and W-135 polysaccharide vaccine is an active immunizing agent used to prevent infection by specific groups of meningococcal bacteria. The vaccine contains purified capsular polysaccharide antigens extracted from Neisseria meningitidis serogroups A, C, Y, and W-135. It works by stimulating the body to produce antibodies against these bacterial groups, providing protection against meningococcal meningitis and meningococcemia. Available in both polysaccharide and conjugate formulations, with conjugate versions linked to carrier proteins such as diphtheria toxoid (MenACWY-D), CRM197 protein (MenACWY-CRM), or tetanus toxoid (MenACWY-TT) for enhanced immunogenicity.
- Brand names
- MenactraMenveoMenQuadfiNmVac4-A/C/Y/W-135
- Other names
- MenACWYMenACWY-DMenACWY-CRMMenACWY-TTACYW135 group meningococcal polysaccharide vaccineACYW-135 group meningococcal polysaccharide vaccineACYW 135 group meningococcal polysaccharide vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal groups A, C, Y, and W-135 polysaccharide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal groups A, C, Y, and W-135 polysaccharide vaccine.